Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration

被引:30
|
作者
Hikichi, Taiichi [1 ]
Agarie, Mitsuko [2 ]
机构
[1] Hikichi Eye Clin, Sapporo, Hokkaido, Japan
[2] Carl Zeiss Meditec Co Ltd, Tokyo, Japan
关键词
anti-VEGF; choriocapillaris; neovascular age-related macular degeneration; optical coherence tomography angiography; vessel density; COHERENCE TOMOGRAPHY ANGIOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY; RETINAL-PIGMENT EPITHELIUM; FOVEAL AVASCULAR ZONE; ANTI-VEGF TREATMENT; QUANTITATIVE-ANALYSIS; VASCULAR DENSITY; RANIBIZUMAB; ATROPHY;
D O I
10.1167/iovs.18-24522
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. To investigate macular vascular alterations by using optical coherence tomography angiography (OCTA) in patients with a history of long-term anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD). METHODS. Japanese patients with nAMD with a history of long-term anti-VEGF monotherapy at study entry were studied retrospectively. OCTA images were obtained, and the vessel densities (mm(-1)) of the superficial capillary plexus, deep capillary plexus (DCP), choriocapillaris (CC), and the plexus foveal avascular zone area (mm(2)) were calculated. RESULTS. One hundred twenty-four eyes (124 patients) were included. The mean +/- standard deviation follow-up period between the first and last OCTA imaging sessions was 14.5 +/- 3.1 months; the duration of the anti-VEGF monotherapy before the first OCTA imaging session was 68.0 +/- 23.6 months, with a mean of 3.6 +/- 3.0 injections during the follow-up period. The vessel densities of the DCP and CC significantly decreased (P = 0.001 and P = 0.009, respectively) from 10.62 +/- 2.72 mm(-1) and 11.84 +/- 1.79 mm(-1) to 9.44 +/- 2.88 mm(-1) and 11.18 +/- 2.12 mm(-1). Such findings were not observed in 63 control eyes. CONCLUSIONS. The DCP and CC deteriorate during treatment. This information may guide future treatment strategies for nAMD, such as the need to protect the capillaries to maintain visual acuity after long-term treatment. Prospective, controlled trials are required to confirm our findings.
引用
收藏
页码:1088 / 1095
页数:8
相关论文
共 50 条
  • [1] Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
    Solomon, Sharon D.
    Lindsley, Kristina
    Vedula, Satyanarayana S.
    Krzystolik, Magdalena G.
    Hawkins, Barbara S.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (03):
  • [2] Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
    Solomon, Sharon D.
    Lindsley, Kristina
    Vedula, Satyanarayana S.
    Krzystolik, Magdalena G.
    Hawkins, Barbara S.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (08):
  • [3] Combination Therapy for Neovascular Age-related Macular Degeneration Refractory to Anti-Vascular Endothelial Growth Factor Agents
    Tozer, Kevin
    Roller, A. Brock
    Chong, Lawrence P.
    Sadda, SriniVas
    Folk, James C.
    Mahajan, Vinit B.
    Russell, Stephen R.
    Boldt, H. Culver
    Sohn, Elliott H.
    OPHTHALMOLOGY, 2013, 120 (10) : 2029 - 2034
  • [4] Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration
    Moreira Kanadani, Tereza Cristina
    dos Reis Veloso, Carlos Eduardo
    Dorairaj, Syril
    Nehemy, Marcio Bittar
    OPHTHALMIC RESEARCH, 2017, 58 (01) : 18 - 26
  • [5] Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration
    Cho, Han Joo
    Park, Sang Min
    Kim, Jaemin
    Nah, Seung Kwan
    Lee, Jihyun
    Lee, Dong Won
    Kim, Jong Woo
    ACTA OPHTHALMOLOGICA, 2021, 99 (04) : E540 - E546
  • [6] Disparities in access to anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration
    Finger, Robert P.
    Xie, Jing
    Fotis, Kathy
    Parikh, Sumit
    Cummins, Rob
    Mitchell, Paul
    Guymer, Robyn H.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 45 (02) : 143 - 151
  • [7] LONG-TERM USE OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Begaj, Tedi
    Jeong, Daeun
    Park, Jong G.
    Runner, Margaret M.
    Capone, Antonio
    Dass, A. Bawa
    Drenser, Kimberly A.
    Faia, Lisa J.
    Farley, Nathan D.
    Garretson, Bruce R.
    Hassan, Tarek S.
    Mahmoud, Tamer H.
    Margherio, Alan
    Raphaelian, Paul V.
    Randhawa, Sandeep
    Ruby, Alan J.
    Sneed, Scott
    Rao, Prethy
    Wolfe, Jeremy D.
    Williams, George A.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2024, 44 (02): : 222 - 229
  • [8] Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration (Review)
    Sunaga, Tomiko
    Maeda, Masayuki
    Saulle, Rosella
    Ng, Sueko M.
    Sato, Miki Takenaka
    Hasegawa, Takeshi
    Mason, Andrew N.
    Noma, Hisashi
    Ota, Erika
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2024, (06):
  • [9] Patterns of anti-vascular endothelial growth factor discontinuation in neovascular age-related macular degeneration
    Basilious, Amy
    Smuck, Bobbi
    Duncan, Julie
    Malvankar-Mehta, Monali S.
    Juncal, Verena R.
    Hooper, Phil
    Sheidow, Tom G.
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2024, 59 (02): : e161 - e169
  • [10] Understanding Variation in Response to Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration
    Maguire, Maureen G.
    JAMA OPHTHALMOLOGY, 2018, 136 (08) : 884 - 885